Long-Term Results of Excision Followed by Radiofrequency Ablation as the Sole Means of Local Therapy for Breast Cancer
- 279 Downloads
Clinical trials have yet to find a size or grade of invasive cancer which can be treated with lumpectomy alone due to the higher local recurrence (LR) rate without radiation (XRT). Excision followed by radiofrequency ablation (eRFA) is an intraoperative method which utilizes heat to create an additional tumor-free zone around the lumpectomy cavity. We hypothesized that eRFA after lumpectomy for invasive breast cancer could reduce the need for re-excision in close margins and potentially maintain local control without the need for XRT.
This institutional review board-approved study from July 2002 to December 2010 involved patients undergoing eRFA. A standard lumpectomy was performed and then the RFA probe was deployed 1 cm circumferentially into the walls of the lumpectomy cavity and maintained at 100 °C for 15 min. Validated doppler sonography was used to determine final ablation size.
Seventy-three patients (mean age of 68.8 ± 10.9 years) with invasive cancer who had an average tumor size of 1.0 ± 0.54 cm (range of 0.2-2.6 cm) underwent eRFA. Margins were negative in 54, close in 10, focally positive in 6, and grossly positive in 3 patients. Sixteen out of 19 (84 %) of patients with close or positive margins were spared of re-excision. Median follow-up was 55 ± 21 months. Only one patient (1.3 %) developed an in site recurrence. There were three recurrences, elsewhere.
Long-term follow-up suggests that eRFA may reduce the need for re- excision as well as reduce LR for invasive breast cancer treated without XRT.
KeywordsSentinel Lymph Node Biopsy Invasive Ductal Carcinoma Positive Margin Ipsilateral Breast Tumor Recurrence Completion Axillary Lymph Node Dissection
This work was funded by grants from the QVC/FFANY, AngioDynamics, Inc. and the State of Arkansas Oversight Committee on Breast Cancer Research.
- 10.Vicini F, Beitsch PD, Quiet CA, et al. Three-year analysis of treatment efficacy, cosmesis, and toxicity by the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial in patients treated with accelerated partial breast irradiation (APBI). Cancer. 2008;112:758–66.PubMedCrossRefGoogle Scholar
- 13.Klimberg VS, Bland K, Westbrook K. Needle localization breast biopsy. In: Atlas of breast surgical techniques. New York: Elsevier, 2010.Google Scholar
- 16.Recht A, Silver B, Schnitt SJ, Connolly J, Hellman S, Harris JR. Breast relapse following primary radiation therapy for early breast cancer: I. Classification, frequency and salvage. Int J Radiat Oncol Biol Phys. 1985;31:1341–6.Google Scholar
- 17.Blichert-Toft M, Rose C, Andersen JA, et al. Danish randomized trial comparing breast conservation therapy with mastectomy: six years of life-table analysis. J Natl Cancer Inst Monogr. 1992;1:19–25.Google Scholar
- 37.Fowble B, Solin LJ, Schultz DJ, Rubenstein J, Goodman RL. Breast recurrence following conservative surgery and radiation: patterns of failure, prognosis, and pathologic findings from mastectomy specimens with implications for treatment. Int J Radiat Oncol Biol Phys. 1990;19:833–42.PubMedCrossRefGoogle Scholar
- 44.Vicini FA, Chen P, Wallace M, et al. Interim cosmetic results and toxicity using 3D conformal external beam radiotherapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys. 2007;69:1124–30.PubMedCrossRefGoogle Scholar
- 47.Strnad V, Hildebrandt G, Potter R, et al. Accelerated partial breast irradiation: 5-year results of the German–Austrian multicenter phase II trial using interstitial multicatheter brachytherapy alone after breast-conserving surgery. Int J Radiat Oncol Biol Phys. 2011;80:17–24.PubMedCrossRefGoogle Scholar